Poly Pharmaceuticals Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Poly Pharmaceuticals

Access the complete profile.

Poly Pharmaceuticals Fast Facts

Revenue	$100 - $500 million    See Exact Annual Revenue
Employees	10 - 100Exact Company Size
Primary Industry	4242 Drugs & Druggists' Sundries Merchant Wholesalers
Additional NAICS Codes	325412 Pharmaceutical Preparation Manufacturing
Address	2720 Cullom Blvd Se Owens Cross Rds, AL 35763

Note: Revenues for privately held companies are statistical evaluations.


Poly Pharmaceuticals's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Poly Pharmaceuticals's annual revenues are $100 - $500 million (see exact revenue data)
• What industry is the company in?
  • Poly Pharmaceuticals is classified as operating in the Drugs & Druggists' Sundries Merchant Wholesalers industry, NAICS Code 4242.

Poly Pharmaceuticals Annual Revenue and Growth Rate

Poly Pharmaceuticals	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2025	$100 - $500 million Details in Premium Report
2024
2023
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Poly Pharmaceuticals's revenues are gauged from an analysis of company filings.

Poly Pharmaceuticals's Income Statement (based on Industry Averages)

Poly Pharmaceuticals P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Poly Pharmaceuticals is developing and marketing. Poly Pharmaceuticals doesn't have any recent trademark applications, indicating Poly Pharmaceuticals is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
ENDAL Cough treatment preparations; preparations for treating colds	09/09/2022
POLY-TUSSIN Pharmaceutical preparations for relief of cough and nasal congestion due to common cold, upper respiratory tract congestion associated with common cold, influenza, bronchitis, and sinusitis	12/30/2019
DECONEX Pharmaceutical preparations for relief of symptoms due to the common cold and allergies	04/29/2014

See all trademarks and details in the Full Report.

Market Share of Poly Pharmaceuticals's Largest Competitors

A competitive analysis shows these companies are in the same general field as Poly Pharmaceuticals, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
AMERISOURCEBERGEN	Conshohocken, PA	100
MCKESSON	Irving, TX	58
CARDINAL HEALTH 119	Dublin, OH	42
TAKEDA PHARMACEUTICALS AMERICA	Lexington, MA	31
CATALENT PHARMA SOLUTIONS	Somerset, NJ	13
OWENS & MINOR DISTRIBUTION	Mechanicsville, VA	11
J M SMITH	Spartanburg, SC	3
DAIICHI SANKYO	Basking Ridge, NJ	3
HIKMA PHARMACEUTICALS USA	Berkeley Heights, NJ	2

Nearby Competitors

These companies are similar in business line and location to Poly Pharmaceuticals. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
POLY PHARMACEUTICALS	Owens Cross Rds, AL	100
ALLISON WHOLESALE	Paint Rock, AL	94
MSOLUTIONS	Madison, AL	16
ZANAY	Hampton Cove, AL	3
MONTE SANO	Owens Cross Roads, AL	2

Future Competition: Poly Pharmaceuticals's Fastest Growing Competitors

These companies are in the same general field as Poly Pharmaceuticals and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)